UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 84

Sortiert nach

Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis

Diabetologia, 2008-06, Vol.51 (6), p.941-951

2008

Volltextzugriff (PDF)

HTA330 EU HTA: How Will Joint Clinical Assessment (JCA) Address the Specifics of Gene Therapies?

Value in health, 2023-12, Vol.26 (12), p.S384

2023

Volltextzugriff (PDF)

HPR163 Joint Scientific Consultation (JSC) and Joint Clinical Assessment (JCA) - A Better Road to Access?

Value in health, 2022-12, Vol.25 (12), p.S262-S262

2022

Volltextzugriff (PDF)

Access to medicine, reimbursement and pricing in germany: what are the implications of amnog?

Value in health, 2015-05, Vol.18 (3), p.A96-A96

2015

Volltextzugriff (PDF)

Rapid Relative Effectiveness Assessment of Pharmaceuticals: Transferability and Completeness of Information Derived From Global Value Dossiers To Complete A Eunethta Submission

Value in health, 2014-11, Vol.17 (7), p.A440-A440

2014

Volltextzugriff (PDF)

Impact of the German Amnog Evaluation on Drug Prices: Correlation of Rebate?

Value in health, 2013-11, Vol.16 (7), p.A473-A473

2013

Volltextzugriff (PDF)

EE231 Use of Biomarkers in Health Care: What Health Economic Methods Are Used to Evaluate Them?

Value in health, 2022-12, Vol.25 (12), p.S98-S98

2022

Volltextzugriff (PDF)

PNS39 Wastage and Costs of Contrast MEDIA in Computed Tomography in the UK: Comparison of MULTI-Dose Versus Single-Dose Bottles

Value in health, 2020-12, Vol.23, p.S650-S650

2020

Volltextzugriff (PDF)

An Economic Evaluation Of Hospital Resource Use And Costs Associated With A New And Innovative Surgery System In Pacemaker And Defibrillator Replacements

Value in health, 2014-05, Vol.17 (3), p.A108-A108

2014

Volltextzugriff (PDF)

PRO51 USE OF NEW THERAPIES PRIOR TO AUTHORIZATION: REIMBURSEMENT HURDLES IN GERMANY

Value in health, 2020-05, Vol.23, p.S337-S338

2020

Volltextzugriff (PDF)

PBI29 ADVANCED THERAPY MEDICINAL PRODUCTS (ATMP): EUROPEAN REGULATORY FRAMEWORK COMPARED TO GERMANY

Value in health, 2019-05, Vol.22, p.S52-S52

2019

Volltextzugriff (PDF)

PHP43 - EVIDENCE FOR HIGH RISK CLASS MEDICAL DEVICES VERSUS NEW DRUGS IN GERMANY: WHAT’S THE DIFFERENCE?

Value in health, 2018-10, Vol.21, p.S157-S158

2018

Volltextzugriff (PDF)

PMD175 - MARKET ENTRY OF NEW MEDICAL DEVICES IN GERMANY - OUTPATIENT SECTOR

Value in health, 2018-10, Vol.21, p.S273-S273

2018

Volltextzugriff (PDF)

PHP15 - NEW TREATMENT METHODS AND REIMBURSEMENT: EXPERIENCES IN GERMANY 2018

Value in health, 2018-10, Vol.21, p.S153-S153

2018

Volltextzugriff (PDF)

Epidemiology of complications and total treatment costs from diagnosis of Type 2 diabetes in Germany (ROSSO 4)

Experimental and clinical endocrinology & diabetes, 2007-09, Vol.115 (8), p.495

2007

Volltextzugriff (PDF)

New European Medical Device Directive (MDD) Comes Into Effect In 2020: Chances And Consequences For Stakeholders

Value in health, 2017-10, Vol.20 (9), p.A594

2017

Volltextzugriff (PDF)

PMD125 - New European Medical Device Directive (MDD) Comes Into Effect In 2020: Chances And Consequences For Stakeholders

Value in health, 2017-10, Vol.20 (9), p.A594-A594

2017

Volltextzugriff (PDF)

NEW EUROPEAN MEDICAL DEVICE DIRECTIVE AND THE POTENTIAL CONSEQUENCES FOR US AND EUROPEAN MANUFACTURERS

Value in health, 2017-05, Vol.20 (5), p.A252

2017

Volltextzugriff (PDF)

Budget Impact of Niraparib As Maintenance Treatment for Medicare Patients with Recurrent Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer Who are in Complete or Partial Response to Platinum-Based Chemotherapy

Value in health, 2018-05, Vol.21, p.S21

2018

Volltextzugriff (PDF)

PCN51 - Budget Impact of Niraparib As Maintenance Treatment for Medicare Patients with Recurrent Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer Who are in Complete or Partial Response to Platinum-Based Chemotherapy

Value in health, 2018-05, Vol.21, p.S21-S21

2018

Volltextzugriff (PDF)

EE257 Budget Consequences of Five Benign Prostatic Hyperplasia Treatment Options - US Medicare Perspective

Value in health, 2022-07, Vol.25 (7), p.S384

2022

Volltextzugriff (PDF)

TT3 MEDICARE BUDGET IMPACT ANALYSIS OF CONVECTIVE WATER VAPOR ENERGY THERAPY COMPARED TO PROSTATIC URETHRAL LIFT FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

Value in health, 2020-05, Vol.23, p.S386-S386

2020

Volltextzugriff (PDF)

The cost-effectiveness of different management strategies for Type I diabetes : a Swiss perspective

Diabetologia, 2000-01, Vol.43 (1), p.13-26

2000

Volltextzugriff (PDF)

PUK14 COST-EFFECTIVENESS OF CONVECTIVE WATER VAPOR ENERGY THERAPY COMPARED TO PROSTATIC URETHRAL LIFT FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

Value in health, 2019-11, Vol.22, p.S915-S915

2019

Volltextzugriff (PDF)

CV3 MECHANICALLY EXPANDED VERSUS SELF-EXPANDING TRANSCATHETER AORTIC VALVE REPLACEMENT IN HIGH-RISK PATIENTS WITH AORTIC STENOSIS: A BUDGET IMPACT ANALYSIS

Value in health, 2019-11, Vol.22, p.S409-S409

2019

Volltextzugriff (PDF)

1 – 25 von 84

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(73)
Mit Volltextzugriff
(78)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(24)
Humans
(22)
Life Sciences & Biomedicine
(16)
Biological And Medical Sciences
(11)
Female
(11)
Medical Sciences
(10)
Internal Medicine
(8)
Male
(8)
Physical Sciences
(6)
Adult
(5)
Aged
(5)
Middle Aged
(5)
Astronomy & Astrophysics
(4)
Diabetes. Impaired Glucose Tolerance
(4)
Endocrine Pancreas. Apud Cells
(4)
Endocrinopathies
(4)
Pregnancy
(4)
Cost Of Illness
(3)
Cost-Benefit Analysis
(3)
Cost-Effectiveness
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis

HTA330 EU HTA: How Will Joint Clinical Assessment (JCA) Address the Specifics of Gene Therapies?

HPR163 Joint Scientific Consultation (JSC) and Joint Clinical Assessment (JCA) - A Better Road to Access?

Access to medicine, reimbursement and pricing in germany: what are the implications of amnog?

Rapid Relative Effectiveness Assessment of Pharmaceuticals: Transferability and Completeness of Information Derived From Global Value Dossiers To Complete A Eunethta Submission

Impact of the German Amnog Evaluation on Drug Prices: Correlation of Rebate?

EE231 Use of Biomarkers in Health Care: What Health Economic Methods Are Used to Evaluate Them?

PNS39 Wastage and Costs of Contrast MEDIA in Computed Tomography in the UK: Comparison of MULTI-Dose Versus Single-Dose Bottles

An Economic Evaluation Of Hospital Resource Use And Costs Associated With A New And Innovative Surgery System In Pacemaker And Defibrillator Replacements

PRO51 USE OF NEW THERAPIES PRIOR TO AUTHORIZATION: REIMBURSEMENT HURDLES IN GERMANY

PBI29 ADVANCED THERAPY MEDICINAL PRODUCTS (ATMP): EUROPEAN REGULATORY FRAMEWORK COMPARED TO GERMANY

PHP43 - EVIDENCE FOR HIGH RISK CLASS MEDICAL DEVICES VERSUS NEW DRUGS IN GERMANY: WHAT’S THE DIFFERENCE?

PMD175 - MARKET ENTRY OF NEW MEDICAL DEVICES IN GERMANY - OUTPATIENT SECTOR

PHP15 - NEW TREATMENT METHODS AND REIMBURSEMENT: EXPERIENCES IN GERMANY 2018

Epidemiology of complications and total treatment costs from diagnosis of Type 2 diabetes in Germany (ROSSO 4)

New European Medical Device Directive (MDD) Comes Into Effect In 2020: Chances And Consequences For Stakeholders

PMD125 - New European Medical Device Directive (MDD) Comes Into Effect In 2020: Chances And Consequences For Stakeholders

NEW EUROPEAN MEDICAL DEVICE DIRECTIVE AND THE POTENTIAL CONSEQUENCES FOR US AND EUROPEAN MANUFACTURERS

Budget Impact of Niraparib As Maintenance Treatment for Medicare Patients with Recurrent Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer Who are in Complete or Partial Response to Platinum-Based Chemotherapy

PCN51 - Budget Impact of Niraparib As Maintenance Treatment for Medicare Patients with Recurrent Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer Who are in Complete or Partial Response to Platinum-Based Chemotherapy

EE257 Budget Consequences of Five Benign Prostatic Hyperplasia Treatment Options - US Medicare Perspective

TT3 MEDICARE BUDGET IMPACT ANALYSIS OF CONVECTIVE WATER VAPOR ENERGY THERAPY COMPARED TO PROSTATIC URETHRAL LIFT FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

The cost-effectiveness of different management strategies for Type I diabetes : a Swiss perspective

PUK14 COST-EFFECTIVENESS OF CONVECTIVE WATER VAPOR ENERGY THERAPY COMPARED TO PROSTATIC URETHRAL LIFT FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

CV3 MECHANICALLY EXPANDED VERSUS SELF-EXPANDING TRANSCATHETER AORTIC VALVE REPLACEMENT IN HIGH-RISK PATIENTS WITH AORTIC STENOSIS: A BUDGET IMPACT ANALYSIS

Suchergebnisse filtern